ES2573807T3 - Procedimiento de determinación de susceptibilidad a las infecciones nosocomiales - Google Patents

Procedimiento de determinación de susceptibilidad a las infecciones nosocomiales Download PDF

Info

Publication number
ES2573807T3
ES2573807T3 ES13719912.1T ES13719912T ES2573807T3 ES 2573807 T3 ES2573807 T3 ES 2573807T3 ES 13719912 T ES13719912 T ES 13719912T ES 2573807 T3 ES2573807 T3 ES 2573807T3
Authority
ES
Spain
Prior art keywords
scd127
patient
expression
sample
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13719912.1T
Other languages
English (en)
Spanish (es)
Inventor
Alain Lepape
Fabienne VENET
Astrid VILLARS
Guillaume Monneret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Hospices Civils de Lyon HCL
Original Assignee
Biomerieux SA
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA, Hospices Civils de Lyon HCL filed Critical Biomerieux SA
Application granted granted Critical
Publication of ES2573807T3 publication Critical patent/ES2573807T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B15/00Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00
    • B29B15/08Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00 of reinforcements or fillers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/0266Local curing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C70/00Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
    • B29C70/04Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
    • B29C70/06Fibrous reinforcements only
    • B29C70/10Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres
    • B29C70/16Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres using fibres of substantial or continuous length
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C70/00Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
    • B29C70/04Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
    • B29C70/28Shaping operations therefor
    • B29C70/30Shaping by lay-up, i.e. applying fibres, tape or broadsheet on a mould, former or core; Shaping by spray-up, i.e. spraying of fibres on a mould, former or core
    • B29C70/38Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
    • B29C70/382Automated fiber placement [AFP]
    • B29C70/384Fiber placement heads, e.g. component parts, details or accessories
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C2035/0211Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould resistance heating
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C53/00Shaping by bending, folding, twisting, straightening or flattening; Apparatus therefor
    • B29C53/56Winding and joining, e.g. winding spirally
    • B29C53/58Winding and joining, e.g. winding spirally helically
    • B29C53/581Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material
    • B29C53/582Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material comprising reinforcements, e.g. wires, threads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2101/00Use of unspecified macromolecular compounds as moulding material
    • B29K2101/10Thermosetting resins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/24Condition, form or state of moulded material or of the material to be shaped crosslinked or vulcanised
    • B29K2105/243Partially cured
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Composite Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Textile Engineering (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Robotics (AREA)
  • Thermal Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing & Machinery (AREA)
  • Polymers & Plastics (AREA)
ES13719912.1T 2012-03-23 2013-03-22 Procedimiento de determinación de susceptibilidad a las infecciones nosocomiales Active ES2573807T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1252641 2012-03-23
FR1252641A FR2988479B1 (fr) 2012-03-23 2012-03-23 Procede de determination de la susceptibilite aux infections nosocomiales
PCT/FR2013/050624 WO2013140103A1 (fr) 2012-03-23 2013-03-22 Procédé de détermination de la susceptibilité aux infections nosocomiales

Publications (1)

Publication Number Publication Date
ES2573807T3 true ES2573807T3 (es) 2016-06-10

Family

ID=48237069

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13719912.1T Active ES2573807T3 (es) 2012-03-23 2013-03-22 Procedimiento de determinación de susceptibilidad a las infecciones nosocomiales

Country Status (9)

Country Link
US (2) US9823239B2 (https=)
EP (1) EP2828657B9 (https=)
JP (2) JP6162788B2 (https=)
CN (1) CN104246499B (https=)
AU (1) AU2013237275B2 (https=)
BR (1) BR112014023387B1 (https=)
ES (1) ES2573807T3 (https=)
FR (1) FR2988479B1 (https=)
WO (1) WO2013140103A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
FR3010792B1 (fr) * 2013-09-18 2017-03-17 Biomerieux Sa Procede d'evaluation du risque de mortalite chez les patients qui presentent une reponse inflammatoire systemique (sirs) ou des syndromes septiques
FR3044325B1 (fr) * 2015-12-01 2019-05-03 Biomerieux Procede d'evaluation du risque de complications chez les patients qui presentent un syndrome de reponse inflammatoire systemique (sirs)
CN108922620A (zh) * 2018-06-20 2018-11-30 南华大学 一种手术切口感染风险评估系统
FR3112207A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112208A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112209A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de complication chez un patient
FR3112211A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
AU629958B2 (en) * 1989-06-15 1992-10-15 Immunex Corporation Interleukin-7 receptors
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
ZA200701662B (en) * 2004-07-27 2009-06-24 Medmined Inc Method for measuring the incidence of hospital acquirede infections
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
DE102008000715B9 (de) * 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
UY32038A (es) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
CA2740191A1 (en) * 2008-10-09 2010-04-15 Thomas Ryan A method of estimating risk of severe sepsis in an individual with infection
FR2941240B1 (fr) * 2009-01-19 2013-05-10 Biomerieux Sa Procede pour determiner la sensibilite d'un patient a contracter une infection nosocomiale.
CN102301008B (zh) * 2009-01-19 2015-05-13 生物梅里埃公司 用于确定患者发生医院内感染的易感性以及确立败血性综合征进展的预后的方法
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
EP2941240A1 (en) * 2013-01-03 2015-11-11 Unilever PLC Hair care composition

Also Published As

Publication number Publication date
JP2015513097A (ja) 2015-04-30
US20150064728A1 (en) 2015-03-05
BR112014023387A2 (https=) 2017-06-20
CN104246499B (zh) 2017-05-10
US20180111342A1 (en) 2018-04-26
JP6162788B2 (ja) 2017-07-12
US10725029B2 (en) 2020-07-28
CN104246499A (zh) 2014-12-24
BR112014023387B1 (pt) 2022-05-17
AU2013237275B2 (en) 2018-07-05
FR2988479B1 (fr) 2014-12-19
JP2017198692A (ja) 2017-11-02
WO2013140103A1 (fr) 2013-09-26
EP2828657B9 (fr) 2016-08-24
EP2828657A1 (fr) 2015-01-28
EP2828657B1 (fr) 2016-03-16
JP6458087B2 (ja) 2019-01-23
US9823239B2 (en) 2017-11-21
AU2013237275A1 (en) 2014-10-02
FR2988479A1 (fr) 2013-09-27

Similar Documents

Publication Publication Date Title
ES2573807T3 (es) Procedimiento de determinación de susceptibilidad a las infecciones nosocomiales
ES2434996T3 (es) Métodos de pronóstico en enfermedad renal crónica
ES2738212T3 (es) Procedimiento de predicción de un pronóstico de septicemia
ES2755623T3 (es) Procedimiento de detección de coagulación intravascular diseminada o coagulación intravascular diseminada infecciosa
El Gendy et al. Clinical study of Presepsin and Pentraxin3 in critically ill children
US20200256876A1 (en) KIT FOR IN VITRO OR EX VIVO MEASUREMENT OF THE EXPRESSION OF sCD127 IN A BIOLOGICAL SAMPLE
Tanyanyiwa et al. The influence of ApoE genotype on the lipid profile and lipoproteins during normal pregnancy in a Southern African population
Hagag et al. Clinical significance of assessment of thrombospondin and placenta growth factor levels in patients with sickle cell anemia: two centers Egyptian studies
ES3009588T3 (en) Method for determining the hemoglobin f content of an erythroid cell
BR122021026851B1 (pt) Processo de determinação in vitro da susceptibilidade a infecções nosocomiais
Abdul-Gani et al. CORRELATION COEFFICIENT BETWEEN COVID-19 IMMUNOGLOBULIN AND LABORATORY PARAMETERS
US20230400464A1 (en) Method for assessing the severity of sars
Abdelrahman et al. The diagnostic value of serum level of soluble hemoglobin scavenger receptor CD163 for sepsis in the ICU
Abd El Wahab et al. Assessment of relevant hematological and biochemical parameters associated with toxoplasmosis in children with multi-transfusion for β-thalassemia major and sickle cell anemia
Erturk et al. Clinical Significance of Neutrophil Gelatinase‐Associated Lipocalin in Crimean‐Congo Hemorrhagic Fever
Lamot et al. 36 Serum calprotectin is a novel predictor of bacterial urinary tract infection in a febrile child
DOĞAN et al. Evaluation of Crimean-Congo Hemorrhagic Fever Disease in Amasya Region" Are We Afraid of Ticks?".
Yevtushenko et al. Correlation of IFABP levels with inflammatory markers in children with COVID-19
Cikrikcioglu et al. Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity
Ushida et al. Transgenerational impact of aberrant inflammation in rat pregnancy
YAKOE PLASMODIUM/alciparum MALARIA I!
Abdu et al. search this publication
S Mutlak • Evaluation of Serum Cystatin C in Iraqi Cardiovascular Patients